NR3C1 and hematopoietic and lymphoid system neoplasm: They demonstrated that PI3K inhibitors, rapamycin and LY294002, prevented GC-mediated skin atrophy and synergized well with GCs in blood cancer treatment by blocking GR trans-activation and NF-κB activity but enhancing GR trans-repression [89,90,91].